Sorrento Therapeutics (NASDAQ:SRNE – Get Rating) had its target price reduced by HC Wainwright from $26.00 to $20.00 in a report issued on Friday morning, The Fly reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock. Other analysts also recently issued research reports about the company. Zacks Investment Research raised Sorrento […]
Related Keywords
, First Republic Investment Management Inc , Sorrento Therapeutics Inc , Principal Financial Group Inc , United Financial Inc , Zacks Investment Research , Barclays Plc , Sorrento Therapeutics , Get Rating , Investment Research , Republic Investment Management , Financial Group , United Financial , Nasdaq Srne , Srne , Medical , Lower Price Target , Hc Wainwright ,
comparemela.com © 2020. All Rights Reserved.